Danish weight-loss drug maker Novo Nordisk (NVO) is jumping 5% after the company reported higher-than-expected net income for the fourth quarter. Additionally, the company's CEO now believes that it will be able to introduce a weight loss pill in the U.S. before its key rival does so. The company markets the popular weight-loss drug, Wegovy. Khosro/Shutterstock.com Q4 Profit Beats Expectations as Wegovy Sales More Than Double NVO generated net income of 28.23 billion Danish kroner or $3.98 billion in Q4. Analysts on average had estimated that its bottom line would come in at 26.09 billion Danish kroner. The company's revenue from Wegovy jumped 107% versus the same period a year earlier to 19.87 billion Danish kroner or $2.76 billion. Novo Nordisk's Comments Speaking to CNBC today, NVO CEO Lars Fruergaard Jørgensen said that his company now expects to be able to introduce a weight loss drug in pill form in the U.S. before its top rival in the weight loss category, Eli Lilly (LLY), does so. NVO expects to submit an application for regulatory approval of a weight loss pill in the U.S. “within a couple of months,” the CEO stated. He added that the company could launch the drug in 2026. While we acknowledge the potential of NVO, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than NVO but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. READ ALSO 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock Disclosure: None. This article is originally published at Insider Monkey.